199 related articles for article (PubMed ID: 25491647)
1. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
[TBL] [Abstract][Full Text] [Related]
2. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
3. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
5. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
6. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
Ludovini V; Gori S; Colozza M; Pistola L; Rulli E; Floriani I; Pacifico E; Tofanetti FR; Sidoni A; Basurto C; Rulli A; Crinò L
Ann Oncol; 2008 May; 19(5):883-90. PubMed ID: 18187484
[TBL] [Abstract][Full Text] [Related]
8. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
Shi HZ; Wang YN; Huang XH; Zhang KC; Xi HQ; Cui JX; Liu GX; Liang WT; Wei B; Chen L
World J Gastroenterol; 2017 Mar; 23(10):1836-1842. PubMed ID: 28348489
[TBL] [Abstract][Full Text] [Related]
9. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
[TBL] [Abstract][Full Text] [Related]
10. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
12. Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels.
Fabricio ASC; Michilin S; Zancan M; Agnolon V; Peloso L; Dittadi R; Scapinello A; Ceccarelli C; Gion M
Scand J Clin Lab Invest; 2019 Jul; 79(4):260-267. PubMed ID: 30982358
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
Clin Breast Cancer; 2004 Jun; 5(2):105-16. PubMed ID: 15245613
[TBL] [Abstract][Full Text] [Related]
14. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Kahlert S; Stieber P
Clin Chim Acta; 2014 Mar; 430():86-91. PubMed ID: 24412321
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
16. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thezenas S; Jacot W
BMC Cancer; 2016 Jul; 16():428. PubMed ID: 27387327
[TBL] [Abstract][Full Text] [Related]
17. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients.
Wang T; Zhou J; Zhang S; Bian L; Hu H; Xu C; Hao X; Liu B; Ye Q; Liu Y; Jiang Z
Clin Chim Acta; 2016 Jul; 458():23-9. PubMed ID: 27109901
[TBL] [Abstract][Full Text] [Related]
18. Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer.
Ma L; Yang HY; Han XH; Li J; Wang F; Zhang CL; Yao JR; Shi YK
Chin Med J (Engl); 2012 Nov; 125(22):4104-10. PubMed ID: 23158151
[TBL] [Abstract][Full Text] [Related]
19. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
Zhang Z; Li C; Fan H; Xiang Q; Xu L; Liu Q; Zhou S; Xie Q; Chen S; Mu G; Cui Y
Breast Cancer Res Treat; 2018 Dec; 172(3):513-521. PubMed ID: 30159787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
